- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05034952
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
December 2, 2022 updated by: Vertex Pharmaceuticals Incorporated
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
303
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Arizona Research Center
-
-
California
-
Pasadena, California, United States, 91105
- Lotus Clinical Research
-
-
Maryland
-
Pasadena, Maryland, United States, 21122
- Chesapeake Research Group
-
-
Ohio
-
Dayton, Ohio, United States, 45417
- Midwest Clinical Research Center
-
-
Texas
-
Bellaire, Texas, United States, 77401
- First Surgical Hospital
-
San Antonio, Texas, United States, 78229
- Endeavor Clinical Trials
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- JBR Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
Before Surgery:
- Participant scheduled to undergo an abdominoplasty without collateral procedures
After Surgery:
- Participant is lucid and able to follow commands
- All analgesic guidelines were followed during and after the abdominoplasty
- Abdominoplasty procedure duration <=3 hours without collateral procedures (for example., liposuction)
Key Exclusion Criteria
Before Surgery:
- Prior history of abdominoplasty, intra-abdominal and/or pelvic surgery
- History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
- Any prior surgery within 1 month before the first study drug
After Surgery:
- Participant had medical complications during the abdominoplasty that, in the opinion of the investigator, should preclude randomization
- Participant had collateral procedures during the abdominoplasty
Other protocol defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VX-548
Participants will be randomized to receive different dose levels of VX-548.
|
Tablets for oral administration.
Placebo matched to HB/APAP for oral administration.
|
Active Comparator: Hydrocodone bitartrate/ acetaminophen (HB/APAP)
Participants will receive HB/APAP.
|
Capsules for oral administration.
Placebo matched to VX-548 for oral administration.
|
Placebo Comparator: Placebo
Participants will receive placebos matched to VX-548 and HB/APAP.
|
Placebo matched to HB/APAP for oral administration.
Placebo matched to VX-548 for oral administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time-weighted sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug
Time Frame: 0 to 48 Hours After the First Dose of Study Drug
|
0 to 48 Hours After the First Dose of Study Drug
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug
Time Frame: 0 to 24 Hours After the First Dose of Study Drug
|
0 to 24 Hours After the First Dose of Study Drug
|
Proportions of Participants With >=30 Percent (%), >=50%, and >=70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
Time Frame: At 48 Hours After the First Dose of Study Drug
|
At 48 Hours After the First Dose of Study Drug
|
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to Day 17
|
Day 1 up to Day 17
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 30, 2021
Primary Completion (Actual)
December 5, 2021
Study Completion (Actual)
December 21, 2021
Study Registration Dates
First Submitted
August 27, 2021
First Submitted That Met QC Criteria
August 27, 2021
First Posted (Actual)
September 5, 2021
Study Record Updates
Last Update Posted (Estimate)
December 7, 2022
Last Update Submitted That Met QC Criteria
December 2, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VX21-548-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pain
-
Rajavithi HospitalCompletedTotal Abdominal Hysterectomy ,Pain , Acute Postoperative,Gabapentin , CelecoxibThailand
-
Schulthess KlinikNot yet recruiting
-
Seoul National University HospitalNot yet recruiting
-
Chung-Ang University Gwangmyeong HospitalRecruitingPostoperative Pain, AcuteKorea, Republic of
-
TC Erciyes UniversityCompletedPostoperative Pain, AcuteTurkey
-
Zagazig UniversityRecruiting
-
Mansoura UniversityRecruitingPostoperative Pain, AcuteEgypt
-
University of California, San DiegoActive, not recruitingPostoperative Pain, AcuteUnited States
-
Umraniye Education and Research HospitalNot yet recruiting
-
Sohag UniversityCompletedPostoperative Pain, AcuteEgypt
Clinical Trials on VX-548
-
Vertex Pharmaceuticals IncorporatedActive, not recruiting
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedRecruitingPainful Lumbosacral RadiculopathyUnited States
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedNot yet recruiting
-
Vertex Pharmaceuticals IncorporatedCompletedAcute PainUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedAcute PainUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedAcute PainUnited States